Trump backer busted in Aussie biotech bungle

10 August 2018
| By Outsider |
image
image
expand image

It would seem that when you’re a US Congressman, sitting down with your son to have “the drug talk” can mean something entirely different to what takes place over a suburban kitchen table.

Instead of the usual speeches of “don’t drink and drive” or “there’s a time and place for doing everything … and it’s called university,” Rep. Christopher Collins of New York allegedly told his son something more along the lines of: “The drug-trial results from this Aussie biotech mob, upon whose board I sit by the way, came back negative. Wanna dump 1.4 million shares?”

According to reports, Collins was arrested on federal charges relating to securities fraud last week in a case involving Australian biotech Innate Immunotherapeutics (try saying that three times, really quickly, under water, with a mouth full of marbles.)

A Securities and Exchange Commission complaint against Collins — the first congressional Republican to endorse Trump’s bid for the White House — also details charges against his son Cameron and the father of his son’s girlfriend, Stephen Zarsky. All three have pleaded not guilty to the charges against them.

The SEC complaint says that in June 2017, Rep. Collins passed on non-public information about Innate Immunotherapeutics’ unexpectedly negative drug-trial results to his son. The case says that Cameron Collins sold nearly 1.4 million shares based on non-public information.

The Collins’s next father-son fishing trip will most likely be postponed.

 

Read more about:

AUTHOR

 

Recommended for you

 

MARKET INSIGHTS

sub-bg sidebar subscription

Never miss the latest news and developments in wealth management industry

Squeaky'21

My view is that after 2026 there will be quite a bit less than 10,000 'advisers' (investment advisers) and less than 100...

6 days 19 hours ago
Jason Warlond

Dugald makes a great point that not everyone's definition of green is the same and gives a good example. Funds have bee...

6 days 20 hours ago
Jasmin Jakupovic

How did they get the AFSL in the first place? Given the green light by ASIC. This is terrible example of ASIC's incompet...

1 week ago

AustralianSuper and Australian Retirement Trust have posted the financial results for the 2022–23 financial year for their combined 5.3 million members....

9 months 1 week ago

A $34 billion fund has come out on top with a 13.3 per cent return in the last 12 months, beating out mega funds like Australian Retirement Trust and Aware Super. ...

9 months ago

The verdict in the class action case against AMP Financial Planning has been delivered in the Federal Court by Justice Moshinsky....

9 months 1 week ago

TOP PERFORMING FUNDS

ACS FIXED INT - AUSTRALIA/GLOBAL BOND